Patents by Inventor Alain Beck
Alain Beck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8808999Abstract: The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.Type: GrantFiled: January 18, 2012Date of Patent: August 19, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20130303734Abstract: The present disclosure relates to novel humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the disclosure relates to novel anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The disclosure also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The disclosure also relates to a method for the preparation of such novel humanized antibodies.Type: ApplicationFiled: November 23, 2011Publication date: November 14, 2013Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Nathalie Corvaia, Jean-François Haeuw, Cédric Bes, Alain Beck
-
Publication number: 20120208721Abstract: The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.Type: ApplicationFiled: January 18, 2012Publication date: August 16, 2012Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Patent number: 8168410Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: GrantFiled: March 1, 2011Date of Patent: May 1, 2012Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Patent number: 8101180Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: GrantFiled: February 19, 2009Date of Patent: January 24, 2012Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20110183376Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: March 1, 2011Publication date: July 28, 2011Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane GOETSCH, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Patent number: 7914784Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: GrantFiled: April 10, 2007Date of Patent: March 29, 2011Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Publication number: 20110014122Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: ApplicationFiled: February 19, 2009Publication date: January 20, 2011Applicant: Pierre Fabre MedicamentInventors: Liliane GOETSCH, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20090181042Abstract: The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against Respiratory Syncytial Virus, including subgroups A and B.Type: ApplicationFiled: March 2, 2009Publication date: July 16, 2009Applicant: PIERRE FABRE MEDICAMENTInventors: Nathalie Corvaia, Thien Ngoc Nguyen, Alain Beck, Helene Plotnicky
-
Patent number: 7553485Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: GrantFiled: December 16, 2004Date of Patent: June 30, 2009Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Patent number: 7524627Abstract: The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against Respiratory Syncytial Virus, including subgroups A and B.Type: GrantFiled: November 16, 2007Date of Patent: April 28, 2009Assignee: Pierre Fabre MedicamentInventors: Nathalie Corvaia, Thien Ngoc Nguyen, Alain Beck, Hélène Plotnicky
-
Publication number: 20090036367Abstract: The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against Respiratory Syncytial Virus, including subgroups A and B.Type: ApplicationFiled: November 16, 2007Publication date: February 5, 2009Applicant: PIERRE FABRE MEDICAMENTInventors: Nathalie Corvaia, Thien Nguyen Ngoc, Alain Beck, Helene Plotnicky
-
Publication number: 20080286198Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: April 10, 2007Publication date: November 20, 2008Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-Francois Haeuw, Alain Beck
-
Publication number: 20080063639Abstract: The present invention relates to a method for the prevention or for the treatment of psoriasis comprising administering to a patient in need thereof an effective amount of an isolated antibody, or one of its functional fragments, capable of binding to the human insulin-like growth factor I receptor IGF-IR. The present invention is also directed to said method wherein a second compound selected from the compounds capable of specifically inhibiting the attachment of the EGF to the human epidermal growth factor receptor EGFR, such as an isolated anti-EGFR antibody, or a functional fragment thereof, is administered to the patient in addition to the anti-IGR-IR antibody.Type: ApplicationFiled: April 11, 2007Publication date: March 13, 2008Applicant: PIERRE FABRE MEDICAMENTInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-Francois Haeuw, Alain Beck, Yann Duflos
-
Patent number: 7309494Abstract: The invention concerns novel immunogenic peptides derived from the RSV G protein of the sub-group A or B comprising at least: a first peptide derived from the BRSV G protein of sub-group A or B including at least in position 173, 176, 182 and 186 a cysteine and whereof the C-terminal end includes at most the amino acid in position 192; and a second peptide derived from the RSV protein of sub-group A or B, said second peptide being located downstream of said first protein, so that the immunogenic peptide produced has a disulphide bond linking residues 173 and 186 and a second disulphide bond linking residues 176 and 182.Type: GrantFiled: July 19, 2002Date of Patent: December 18, 2007Assignee: Pierre Fabre MedicamentInventors: Nathalie Corvaia, Thien Nguyen Ngoc, Alain Beck, Hélène Plotnicky
-
Patent number: 7241444Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: GrantFiled: December 16, 2003Date of Patent: July 10, 2007Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Patent number: 7033591Abstract: The invention concerns the use of a membrane fraction of gram-negative bacteria, in particular Klebsiella pnemoniae for preparing a pharmaceutical composition that is immunostimulant and/or capable of inducing an antitumoral immune response, designed in particular for treating and preventing cancers. The invention further comprises methods for preparing said membrane factions and pharmaceutical compositions containing them, in particular combined with anticancer compounds.Type: GrantFiled: March 15, 2000Date of Patent: April 25, 2006Assignee: Pierre Fabre MedicamentInventors: Christine Libon, Nathalie Corvaia, Alain Beck, Jean-Yves Bonnefoy
-
Publication number: 20050249730Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R.Type: ApplicationFiled: December 16, 2004Publication date: November 10, 2005Inventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20050084906Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: ApplicationFiled: December 16, 2003Publication date: April 21, 2005Inventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-Francois Haeuw, Alain Beck
-
Publication number: 20040175395Abstract: The invention concerns novel immunogenic peptides derived from the RSV G protein of the sub-group A or B comprising at least: a first peptide derived from the BRSV G protein of sub-group A or B including at least in position 173, 176, 182 and 186 a cysteine and whereof the C-terminal end includes at most the amino acid in position 192; and a second peptide derived from the RSV protein of sub-group A or B, said second peptide being located downstream of said first protein, so that the immunogenic peptide produced has a disulphide bond linking residues 173 and 186 and a second disulphide bond linking residues 176 and 182.Type: ApplicationFiled: January 20, 2004Publication date: September 9, 2004Inventors: Nathalie Corvaia, Thien Nyugen Ngoc, Alain Beck, Helene Plotnicky